Nicholas Hornstein
@GIMedOnc
GI Med Oncologist @NorthwellHealth via Fellow @MDAndersonNews + IM @UCLAHealth
| CUMC ‘18 | Interests: ML/AI, Clinical Trials, CRC | COI:
加入 November 2020
847 正在關注 2.7K 粉絲
He may be a NET guy (no one is perfect), but this is the conversation now for MSI-H CRC.
Authors’ conclusion: The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC (which is misleading).
Correct conclusion: Atezolizumab led to inferior outcomes compared to FFX/bev plus atezo despite the well-established superiority of ICI over cytotoxic chemotherapy in MSI-H colorectal cancer, calling into question its role as the ICI of choice in this population.
Should this make you worried about ATOMIC? The answer should be 100%
My go-to for adjuvant therapy in MSI-H colon cancer is off-label PD-1 or on our clinical trial of toripalimab monotherapy led by my colleague Dr Emiloju @WinshipAtEmory
顯示更多
